$BBIO
BridgeBio Pharma, Inc.

2020 Q1 Form 10-K Financial Statement

#000156459020008260 Filed on March 03, 2020

View on sec.gov

Income Statement

Concept 2020 Q1 2019 Q4 2019
Revenue $0.00 $13.82M $40.56M
YoY Change
Cost Of Revenue $0.00 $2.500M
YoY Change
Gross Profit $13.82M $38.06M
YoY Change
Gross Profit Margin 100.0% 93.84%
Selling, General & Admin $34.26M $34.97M $94.35M
YoY Change 81.27% 143.18% 116.46%
% of Gross Profit 253.04% 247.91%
Research & Development $68.23M $57.49M $209.9M
YoY Change 3311.25% 12.29% 49.88%
% of Gross Profit 415.99% 551.62%
Depreciation & Amortization $859.0K
YoY Change 243.6%
% of Gross Profit 2.26%
Operating Expenses $102.5M $92.46M $306.8M
YoY Change 5024.35% 40.97% 67.05%
Operating Profit -$102.5M -$78.64M -$266.2M
YoY Change 60.76% 19.9% 44.96%
Interest Expense $4.010M -$5.360M $8.765M
YoY Change 139.98% -26900.0% 244.13%
% of Operating Profit
Other Income/Expense, Net -$1.595M -$160.0K -$22.35M
YoY Change -71.94% -94.67% -257.26%
Pretax Income -$104.1M -$84.15M -$288.6M
YoY Change 49.88% 70.9% -270.31%
Income Tax $0.00
% Of Pretax Income
Net Earnings -$104.1M -$73.46M -$288.6M
YoY Change 49.9% 90.11% 70.31%
Net Earnings / Revenue -531.55% -711.5%
Basic Earnings Per Share
Diluted Earnings Per Share -$779.7K -$623.4K -$2.479M
COMMON SHARES
Basic Shares Outstanding 123.8M
Diluted Shares Outstanding

Balance Sheet

Concept 2020 Q1 2019 Q4 2019
SHORT-TERM ASSETS
Cash & Short-Term Investments $905.2M $546.0M $546.0M
YoY Change 142.68% 25.2% 25.2%
Cash & Equivalents $757.0M $363.8M $363.8M
Short-Term Investments $148.1M $182.2M $182.2M
Other Short-Term Assets $19.80M $22.60M $22.60M
YoY Change 108.42% 1002.44% 145.65%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $925.0M $568.6M $568.6M
YoY Change 141.83% 27.72% 27.72%
LONG-TERM ASSETS
Property, Plant & Equipment $24.60M $5.625M $5.600M
YoY Change 1194.74% 257.14% 250.0%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $23.20M $31.10M $31.10M
YoY Change 85.6% 81.87%
Other Assets $17.00M $26.29M $26.30M
YoY Change 269.57% 2305.12% 2290.91%
Total Long-Term Assets $64.80M $63.06M $63.10M
YoY Change 242.86% 219.79% 220.3%
TOTAL ASSETS
Total Short-Term Assets $925.0M $568.6M $568.6M
Total Long-Term Assets $64.80M $63.06M $63.10M
Total Assets $989.8M $631.7M $631.7M
YoY Change 146.59% 35.86% 35.88%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $13.10M $8.852M $8.900M
YoY Change 6.5% -34.47% -34.07%
Accrued Expenses $48.30M $3.020M $47.50M
YoY Change 159.68% 43.81% 214.57%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $64.90M $60.39M $60.40M
YoY Change 82.82% 85.36% 85.28%
LONG-TERM LIABILITIES
Long-Term Debt $461.3M $91.79M $91.80M
YoY Change 740.26% 68.4% 68.44%
Other Long-Term Liabilities $11.50M $3.527M $3.500M
YoY Change 2775.0% 612.53% 600.0%
Total Long-Term Liabilities $472.8M $95.32M $95.30M
YoY Change 754.97% 73.3% 73.27%
TOTAL LIABILITIES
Total Short-Term Liabilities $64.90M $60.39M $60.40M
Total Long-Term Liabilities $472.8M $95.32M $95.30M
Total Liabilities $609.1M $155.7M $223.2M
YoY Change 308.24% 77.79% 48.7%
SHAREHOLDERS EQUITY
Retained Earnings -$440.0M
YoY Change 145.22%
Common Stock $848.2M
YoY Change 71.59%
Preferred Stock
YoY Change
Treasury Stock (at cost) $75.00M
YoY Change
Treasury Stock Shares $2.415M $0.00
Shareholders Equity $380.7M $408.5M $408.5M
YoY Change
Total Liabilities & Shareholders Equity $989.8M $631.7M $631.7M
YoY Change 146.59% 35.86% 35.88%

Cashflow Statement

Concept 2020 Q1 2019 Q4 2019
OPERATING ACTIVITIES
Net Income -$104.1M -$73.46M -$288.6M
YoY Change 49.9% 90.11% 70.31%
Depreciation, Depletion And Amortization $859.0K
YoY Change 243.6%
Cash From Operating Activities -$83.92M -$76.21M -$253.6M
YoY Change 41.9% -35.79% 85.58%
INVESTING ACTIVITIES
Capital Expenditures $4.477M -$1.750M $2.638M
YoY Change 948.48% -41.67% 21.12%
Acquisitions
YoY Change
Other Investing Activities $42.50M -$15.16M $1.716M
YoY Change 430.07% -160.0%
Cash From Investing Activities $38.02M -$16.90M -$217.3M
YoY Change -1666.67% 188.4% 932.77%
FINANCING ACTIVITIES
Cash Dividend Paid $997.0K
YoY Change
Common Stock Issuance & Retirement, Net $75.00M
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 439.2M 42.90M 398.8M
YoY Change -26700.42% -91.17% -20.49%
NET CHANGE
Cash From Operating Activities -83.92M -76.21M -253.6M
Cash From Investing Activities 38.02M -16.90M -217.3M
Cash From Financing Activities 439.2M 42.90M 398.8M
Net Change In Cash 393.3M -50.21M -72.05M
YoY Change -722.09% -113.9% -120.95%
FREE CASH FLOW
Cash From Operating Activities -$83.92M -$76.21M -$253.6M
Capital Expenditures $4.477M -$1.750M $2.638M
Free Cash Flow -$88.40M -$74.46M -$256.2M
YoY Change 48.4% -35.64% 84.57%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2019 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
94301
CY2019 dei Entity Ex Transition Period
EntityExTransitionPeriod
false
CY2019 dei Entity Shell Company
EntityShellCompany
false
CY2018Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
1093000
CY2018Q4 us-gaap Assets
Assets
464941000
CY2018Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
13509000
CY2018Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
4047000
CY2018Q4 bbio Accrued Research And Development Liabilities Current
AccruedResearchAndDevelopmentLiabilitiesCurrent
8915000
CY2018Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
772000
CY2019Q4 bbio Leo Call Option Liability Current
LEOCallOptionLiabilityCurrent
4078000
CY2019 dei Entity File Number
EntityFileNumber
001-38959
CY2019 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2019Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
631679000
CY2018Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
464941000
CY2019Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2018Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2019Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
25000000
CY2018Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
0
CY2019Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2018Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2019Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2018Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2019Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2018Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2019 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2018Q4 us-gaap Investments In Affiliates Subsidiaries Associates And Joint Ventures
InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures
17050000
CY2018Q4 bbio Accrued Distributions Stockholders Current
AccruedDistributionsStockholdersCurrent
997000
CY2018Q4 bbio Leo Call Option Liability Current
LEOCallOptionLiabilityCurrent
3009000
CY2019Q4 bbio Build To Suit Lease Obligation Current
BuildToSuitLeaseObligationCurrent
8000000
CY2018Q4 us-gaap Liabilities Current
LiabilitiesCurrent
32577000
CY2019Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
848107000
CY2018Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
494231000
CY2019Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
254000
CY2019Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-440031000
CY2018Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-179444000
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
408454000
CY2018Q4 us-gaap Stockholders Equity
StockholdersEquity
314879000
CY2019Q4 us-gaap Minority Interest
MinorityInterest
65279000
CY2018Q4 us-gaap Minority Interest
MinorityInterest
62361000
CY2019Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
473733000
CY2018Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
377240000
CY2019Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000
CY2018Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
97412870
CY2019Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
123658287
CY2018Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
92057704
CY2019Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
123658287
CY2018Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
92057704
CY2019 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
40560000
CY2019 us-gaap Revenue From Contract With Customer Product And Service Extensible List
RevenueFromContractWithCustomerProductAndServiceExtensibleList
us-gaap:LicenseMember
CY2018 us-gaap Revenue From Contract With Customer Product And Service Extensible List
RevenueFromContractWithCustomerProductAndServiceExtensibleList
us-gaap:LicenseMember
CY2017 us-gaap Revenue From Contract With Customer Product And Service Extensible List
RevenueFromContractWithCustomerProductAndServiceExtensibleList
us-gaap:LicenseMember
CY2019 bbio Cost Of License Revenue
CostOfLicenseRevenue
2500000
CY2019 us-gaap Operating Income Loss
OperatingIncomeLoss
-266240000
CY2019 us-gaap Investment Income Interest
InvestmentIncomeInterest
8915000
CY2018 us-gaap Investment Income Interest
InvestmentIncomeInterest
2004000
CY2019 us-gaap Interest Expense
InterestExpense
8765000
CY2018 us-gaap Interest Expense
InterestExpense
2547000
CY2017 us-gaap Interest Expense
InterestExpense
13000
CY2018 us-gaap Deconsolidation Gain Or Loss Amount
DeconsolidationGainOrLossAmount
19327000
CY2019 bbio Business Combination Loss On Asset Acquisitions
BusinessCombinationLossOnAssetAcquisitions
416000
CY2019 us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
-20869000
CY2018 us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
-275000
CY2019 us-gaap Other Nonoperating Expense
OtherNonoperatingExpense
1210000
CY2018 us-gaap Other Nonoperating Expense
OtherNonoperatingExpense
4300000
CY2019 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2019Q4 us-gaap Marketable Securities Noncurrent
MarketableSecuritiesNoncurrent
31144000
CY2019 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
CY2019 dei Entity Small Business
EntitySmallBusiness
false
CY2019Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
26288000
CY2019 dei Amendment Flag
AmendmentFlag
false
CY2019 dei Entity Central Index Key
EntityCentralIndexKey
0001743881
CY2019Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
22629000
CY2019 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2019 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2019 dei Document Type
DocumentType
10-K
CY2019 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2019
CY2019 dei Trading Symbol
TradingSymbol
BBIO
CY2019 dei Document Period End Date
DocumentPeriodEndDate
2019-12-31
CY2019 dei Entity Registrant Name
EntityRegistrantName
BridgeBio Pharma, Inc.
CY2019 dei Document Transition Report
DocumentTransitionReport
false
CY2019 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2019 dei Local Phone Number
LocalPhoneNumber
391-9740
CY2019 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
84-1850815
CY2019 dei Entity Address City Or Town
EntityAddressCityOrTown
Palo Alto
CY2020Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
123765465
CY2019 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2019 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2019Q2 dei Entity Public Float
EntityPublicFloat
0
CY2019 dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
CY2019 dei Entity Address Address Line1
EntityAddressAddressLine1
421 Kipling Street
CY2019 dei City Area Code
CityAreaCode
(650)
CY2019 dei Document Annual Report
DocumentAnnualReport
true
CY2019 dei Security12b Title
Security12bTitle
Common Stock, par value $0.001 per share
CY2019 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2019Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
363773000
CY2018Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
436086000
CY2019Q4 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
182220000
CY2019Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
13317000
CY2019Q4 bbio Accrued Research And Development Liabilities Current
AccruedResearchAndDevelopmentLiabilitiesCurrent
20896000
CY2019Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
2222000
CY2019Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
3020000
CY2018Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
1328000
CY2019Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
8852000
CY2018Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1575000
CY2018Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
9137000
CY2019Q4 us-gaap Assets Current
AssetsCurrent
568622000
CY2018Q4 us-gaap Assets Current
AssetsCurrent
445223000
CY2019Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
5625000
CY2019Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
91791000
CY2018Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
54507000
CY2019Q4 us-gaap Liabilities Current
LiabilitiesCurrent
60385000
CY2019Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
3527000
CY2019Q4 us-gaap Liabilities
Liabilities
155703000
CY2019Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2019Q4 us-gaap Temporary Equity Carrying Amount Including Portion Attributable To Noncontrolling Interests
TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests
2243000
CY2019Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2019Q4 us-gaap Common Stock Value
CommonStockValue
124000
CY2017 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
30556000
CY2018 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
43587000
CY2018 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
140073000
CY2019 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
94353000
CY2019Q4 us-gaap Assets
Assets
631679000
CY2018Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
495000
CY2018Q4 us-gaap Liabilities
Liabilities
87579000
CY2018Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2018Q4 us-gaap Temporary Equity Carrying Amount Including Portion Attributable To Noncontrolling Interests
TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests
122000
CY2018Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2018Q4 us-gaap Common Stock Value
CommonStockValue
92000
CY2019 us-gaap Operating Expenses
OperatingExpenses
306800000
CY2017 us-gaap Investment Income Interest
InvestmentIncomeInterest
39000
CY2019 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
209947000
CY2017 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
13302000
CY2018 us-gaap Operating Expenses
OperatingExpenses
183660000
CY2017 us-gaap Operating Expenses
OperatingExpenses
43858000
CY2018 us-gaap Operating Income Loss
OperatingIncomeLoss
-183660000
CY2017 us-gaap Operating Income Loss
OperatingIncomeLoss
-43858000
CY2018 us-gaap Share Based Compensation
ShareBasedCompensation
6067000
CY2019 us-gaap Share Based Compensation
ShareBasedCompensation
21374000
CY2019 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-22345000
CY2018 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
14209000
CY2017 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
26000
CY2019 us-gaap Profit Loss
ProfitLoss
-288585000
CY2018 us-gaap Profit Loss
ProfitLoss
-169451000
CY2017 us-gaap Profit Loss
ProfitLoss
-43832000
CY2019 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
-27998000
CY2018 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
-38702000
CY2017 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
-13267000
CY2019 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-260587000
CY2018 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-130749000
CY2017 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-30565000
CY2019 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-2.48
CY2018 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-2.12
CY2017 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.00
CY2019 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
105099089
CY2018 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
61767414
CY2017 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
30598983
CY2019 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
254000
CY2019 us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
-288331000
CY2018 us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
-169451000
CY2017 us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
-43832000
CY2019 us-gaap Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
-27998000
CY2018 us-gaap Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
-38702000
CY2017 us-gaap Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
-13267000
CY2019 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-260333000
CY2018 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-130749000
CY2017 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-30565000
CY2016Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
17484000
CY2017 bbio Adjustments To Additional Paid In Capital Decrease From Distributions To Unit Holders
AdjustmentsToAdditionalPaidInCapitalDecreaseFromDistributionsToUnitHolders
-2148000
CY2017 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
541000
CY2017 bbio Stock Issued During Period Value Conversion Of Promissory Note
StockIssuedDuringPeriodValueConversionOfPromissoryNote
4000000
CY2017 bbio Adjustments To Additional Paid In Capital Capital Transaction Upon Merger
AdjustmentsToAdditionalPaidInCapitalCapitalTransactionUponMerger
4532000
CY2017 us-gaap Adjustments To Additional Paid In Capital Dividends In Excess Of Retained Earnings
AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings
-4532000
CY2017 bbio Stock Issued During Repayment Of Nonrecourse Notes
StockIssuedDuringRepaymentOfNonrecourseNotes
132000
CY2017 bbio Issuance Repurchase Of Noncontrolling Interest
IssuanceRepurchaseOfNoncontrollingInterest
1444000
CY2017 us-gaap Minority Interest Period Increase Decrease
MinorityInterestPeriodIncreaseDecrease
769000
CY2017 bbio Net Income Loss Excluding Redeemable Noncontrolling Interests Net Income Loss
NetIncomeLossExcludingRedeemableNoncontrollingInterestsNetIncomeLoss
-41075000
CY2017Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
88349000
CY2018 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
3183000
CY2018 bbio Issuance Repurchase Of Noncontrolling Interest
IssuanceRepurchaseOfNoncontrollingInterest
55245000
CY2018 us-gaap Minority Interest Period Increase Decrease
MinorityInterestPeriodIncreaseDecrease
51698000
CY2018 bbio Noncontrolling Interest Increase From Deconsolidation
NoncontrollingInterestIncreaseFromDeconsolidation
688000
CY2018 bbio Net Income Loss Excluding Redeemable Noncontrolling Interests Net Income Loss
NetIncomeLossExcludingRedeemableNoncontrollingInterestsNetIncomeLoss
-156921000
CY2019 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
10902000
CY2019 bbio Stock Issued During Repayment Of Nonrecourse Notes
StockIssuedDuringRepaymentOfNonrecourseNotes
179000
CY2019 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
3937000
CY2019 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Employee Stock Purchase Program Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition
351000
CY2019 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
16000
CY2019 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
921000
CY2019 bbio Issuance Repurchase Of Noncontrolling Interest
IssuanceRepurchaseOfNoncontrollingInterest
1206000
CY2019 us-gaap Minority Interest Period Increase Decrease
MinorityInterestPeriodIncreaseDecrease
-1803000
CY2019 bbio Net Income Loss Excluding Redeemable Noncontrolling Interests Net Income Loss
NetIncomeLossExcludingRedeemableNoncontrollingInterestsNetIncomeLoss
-285707000
CY2017 us-gaap Share Based Compensation
ShareBasedCompensation
1841000
CY2017 bbio Proceeds From Third Party Investors In Redeemable Convertible Noncontrolling Interests
ProceedsFromThirdPartyInvestorsInRedeemableConvertibleNoncontrollingInterests
2839000
CY2017 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
4301000
CY2018 us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
843000
CY2017 us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
92000
CY2019 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-4657000
CY2018 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
16700000
CY2019 us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
9270000
CY2018 bbio Call Option Expense
CallOptionExpense
3009000
CY2018 bbio Change In Fair Value Of Financial Instruments
ChangeInFairValueOfFinancialInstruments
1146000
CY2019 us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
-1351000
CY2018 us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
-442000
CY2019 bbio Fair Value Of Equity Method Investment
FairValueOfEquityMethodInvestment
-3819000
CY2019 us-gaap Accretion Expense
AccretionExpense
1509000
CY2018 us-gaap Accretion Expense
AccretionExpense
783000
CY2019 us-gaap Research And Development In Process
ResearchAndDevelopmentInProcess
3560000
CY2018 us-gaap Research And Development In Process
ResearchAndDevelopmentInProcess
17922000
CY2019 bbio Call Option Expense
CallOptionExpense
1069000
CY2017 us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
-260000
CY2019 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
13492000
CY2018 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
6100000
CY2019 us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
16929000
CY2017 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
1577000
CY2018 us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
3396000
CY2017 us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
1131000
CY2019 bbio Increase Decrease In Accrued Research And Development Liabilities
IncreaseDecreaseInAccruedResearchAndDevelopmentLiabilities
11981000
CY2018 bbio Increase Decrease In Accrued Research And Development Liabilities
IncreaseDecreaseInAccruedResearchAndDevelopmentLiabilities
5785000
CY2017 bbio Increase Decrease In Accrued Research And Development Liabilities
IncreaseDecreaseInAccruedResearchAndDevelopmentLiabilities
2650000
CY2019 bbio Increase Decrease In Accrued Professional Services
IncreaseDecreaseInAccruedProfessionalServices
1450000
CY2018 bbio Increase Decrease In Accrued Professional Services
IncreaseDecreaseInAccruedProfessionalServices
454000
CY2017 bbio Increase Decrease In Accrued Professional Services
IncreaseDecreaseInAccruedProfessionalServices
-346000
CY2019 us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
1527000
CY2018 us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
2917000
CY2017 us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
356000
CY2019 us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
-65000
CY2018 us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
182000
CY2017 us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
268000
CY2019 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-253587000
CY2018 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-136643000
CY2017 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-40488000
CY2019 us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
212899000
CY2018 us-gaap Cash Divested From Deconsolidation
CashDivestedFromDeconsolidation
2858000
CY2019 us-gaap Payments To Acquire In Process Research And Development
PaymentsToAcquireInProcessResearchAndDevelopment
2500000
CY2018 us-gaap Payments To Acquire In Process Research And Development
PaymentsToAcquireInProcessResearchAndDevelopment
16000000
CY2019 us-gaap Cash Acquired From Acquisition
CashAcquiredFromAcquisition
784000
CY2019 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
2638000
CY2018 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
2178000
CY2017 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
464000
CY2019 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-217253000
CY2018 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-21036000
CY2017 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-464000
CY2019 us-gaap Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
366237000
CY2018 us-gaap Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
95536000
CY2019 bbio Stock Issued No Premium
StockIssuedNoPremium
23309000
CY2018 us-gaap Proceeds From Issuance Of Debt
ProceedsFromIssuanceOfDebt
1000000
CY2017 us-gaap Proceeds From Issuance Of Debt
ProceedsFromIssuanceOfDebt
4000000
CY2019 us-gaap Proceeds From Repayments Of Secured Debt
ProceedsFromRepaymentsOfSecuredDebt
179000
CY2017 us-gaap Proceeds From Repayments Of Secured Debt
ProceedsFromRepaymentsOfSecuredDebt
132000
CY2019 us-gaap Proceeds From Debt Net Of Issuance Costs
ProceedsFromDebtNetOfIssuanceCosts
36939000
CY2018 us-gaap Proceeds From Debt Net Of Issuance Costs
ProceedsFromDebtNetOfIssuanceCosts
56438000
CY2019 us-gaap Proceeds From Minority Shareholders
ProceedsFromMinorityShareholders
23927000
CY2018 us-gaap Proceeds From Issuance Of Redeemable Convertible Preferred Stock
ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock
334998000
CY2017 us-gaap Proceeds From Issuance Of Redeemable Convertible Preferred Stock
ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock
107019000
CY2019 bbio Proceeds From Third Party Investors In Redeemable Convertible Noncontrolling Interests
ProceedsFromThirdPartyInvestorsInRedeemableConvertibleNoncontrollingInterests
1500000
CY2018 bbio Proceeds From Third Party Investors In Redeemable Convertible Noncontrolling Interests
ProceedsFromThirdPartyInvestorsInRedeemableConvertibleNoncontrollingInterests
58430000
CY2018 us-gaap Proceeds From Repayments Of Related Party Debt
ProceedsFromRepaymentsOfRelatedPartyDebt
37000
CY2019 us-gaap Payments Of Dividends
PaymentsOfDividends
997000
CY2017 us-gaap Payments Of Dividends
PaymentsOfDividends
1151000
CY2019 us-gaap Payments For Repurchase Of Redeemable Noncontrolling Interest
PaymentsForRepurchaseOfRedeemableNoncontrollingInterest
55011000
CY2018 us-gaap Payments For Repurchase Of Redeemable Noncontrolling Interest
PaymentsForRepurchaseOfRedeemableNoncontrollingInterest
44234000
CY2018 us-gaap Repayments Of Long Term Debt
RepaymentsOfLongTermDebt
1097000
CY2019 us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
921000
CY2019 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
1788000
CY2018 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
440000
CY2017 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
144000
CY2019 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
398792000
CY2018 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
501548000
CY2017 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
112983000
CY2019 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-72048000
CY2018 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
343869000
CY2017 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
72031000
CY2018Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
436245000
CY2017Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
92376000
CY2016Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
20345000
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
364197000
CY2019 us-gaap Interest Paid Net
InterestPaidNet
6092000
CY2018 us-gaap Interest Paid Net
InterestPaidNet
1574000
CY2019 us-gaap Payments For Tenant Improvements
PaymentsForTenantImprovements
2097000
CY2017 bbio Conversion Of Promissory Note Upon Issuance Of Series C Redeemable Convertible Preferred Units
ConversionOfPromissoryNoteUponIssuanceOfSeriesCRedeemableConvertiblePreferredUnits
4000000
CY2019 bbio Noncash Or Part Noncash Investing Transfer From To Noncontrolling Interest
NoncashOrPartNoncashInvestingTransferFromToNoncontrollingInterest
-28635000
CY2018 bbio Noncash Or Part Noncash Investing Transfer From To Noncontrolling Interest
NoncashOrPartNoncashInvestingTransferFromToNoncontrollingInterest
21596000
CY2017 bbio Noncash Or Part Noncash Investing Transfer From To Noncontrolling Interest
NoncashOrPartNoncashInvestingTransferFromToNoncontrollingInterest
-8200000
CY2019 us-gaap Construction In Progress Expenditures Incurred But Not Yet Paid
ConstructionInProgressExpendituresIncurredButNotYetPaid
8000000
CY2019 bbio Fair Value Of Success Fee Derivative At Issuance Of Term Loan
FairValueOfSuccessFeeDerivativeAtIssuanceOfTermLoan
1148000
CY2018 bbio Conversion Of Redeemable Noncontrolling Interest Into Noncontrolling Interest
ConversionOfRedeemableNoncontrollingInterestIntoNoncontrollingInterest
12252000
CY2018 us-gaap Debt Conversion Converted Instrument Amount1
DebtConversionConvertedInstrumentAmount1
1005000
CY2017 bbio Capital Transaction Upon Merger
CapitalTransactionUponMerger
4532000
CY2018 us-gaap Fair Value Of Assets Acquired
FairValueOfAssetsAcquired
1922000
CY2019 us-gaap Nature Of Operations
NatureOfOperations
<div align="left"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"> <tr> <td valign="top" style="width:5.24%;white-space:nowrap"> <p style="margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">1.</font></p></td> <td valign="top"> <p style="margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><font style="font-weight:normal;"></font>Organization and Description of Business </p></td></tr></table></div> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">BridgeBio Pharma, Inc. (the &#8220;Corporation&#8221;) was formed as a Delaware corporation on May&#160;17, 2019 for the purpose of completing an initial public offering of the Corporation&#8217;s common stock (the &#8220;IPO&#8221;) and related organizational transactions (the &#8220;Reorganization&#8221;) in order to carry on the business of BridgeBio Pharma LLC (&#8220;BBP LLC&#8221;). The Corporation, the reporting entity in these consolidated financial statements, and BBP LLC, the predecessor reporting entity before the completion of the Reorganization and the Corporation&#8217;s wholly-owned subsidiary after the completion of the Reorganization, are collectively referred to as BridgeBio. </p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Since inception, BridgeBio has either created wholly-owned subsidiaries or has made investments in certain controlled entities, including partially-owned subsidiaries for which BridgeBio has a majority voting interest and variable interest entities (&#8220;VIEs&#8221;) for which BridgeBio is the primary beneficiary (collectively, &#8220;we&#8221;, &#8220;our&#8221;, &#8220;us&#8221;). BridgeBio is headquartered in Palo Alto, California.</p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">BridgeBio was established to identify and advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. BridgeBio&#8217;s pipeline of programs spans early discovery to late-stage development. </p> <p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Reorganization and Initial Public Offering</p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On July 1, 2019, the Corporation closed the IPO of its common stock. As part of the IPO, the Corporation issued and sold 23,575,000 shares of its common stock, which included 3,075,000 shares sold pursuant to the exercise of the underwriters&#8217; over-allotment option, at a public offering price of $17.00 per share. The Corporation received net proceeds of approximately $366.2 million from the IPO, after deducting underwriters&#8217; discounts and commissions of $28.1 million and offering costs of $6.5 million.</p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Upon the closing of the IPO on July 1, 2019, BridgeBio completed the Reorganization, whereby all unitholders of BBP LLC exchanged their units for shares of common stock of the Corporation, and BBP LLC became a wholly-owned subsidiary of the Corporation. Subsequent to the Reorganization, as the sole managing member, the Corporation operates and controls all of BBP LLC&#8217;s businesses and affairs. See Note&#160;3 for additional details.</p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The results of operations and cash flows prior to the IPO closing on July 1, 2019 relate to BBP LLC, its subsidiaries and controlled entities. Subsequent to the IPO closing, the information relates to the Corporation, its subsidiaries and controlled entities. All share and per share amounts in these consolidated financial statements and related notes have been retroactively adjusted, where applicable, for all periods presented to give effect to the exchange ratio applied in connection with the Reorganization. See Note&#160;3 for additional details.</p>
CY2019 us-gaap Prior Period Reclassification Adjustment Description
PriorPeriodReclassificationAdjustmentDescription
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;">&nbsp;</p> <p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Factors Affecting Comparability </p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our historical financial condition and results of operations for the&#160;periods presented may not be comparable, either between&#160;periods or going forward due to the factors described below. </p> <p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Eidos Therapeutics, Inc. Transactions: </p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In February 2018, we entered into a note and warrant purchase agreement with Eidos pursuant to which Eidos issued a convertible promissory note, or the Eidos Note, with the principal amount of $10.0&#160;million and a warrant to purchase a number of shares of preferred stock equal to $4.0&#160;million at the price paid by investors in the next equity financing, or the Eidos Warrant. In March 2018, we transferred 10% or $1.0&#160;million of our interest in the Eidos Note and the Eidos Warrant to a minority stockholder of Eidos. In March 2018, the Eidos Note was redeemed into shares of Series B redeemable convertible preferred stock of Eidos at a 30% discount to the price paid by other investors. In conjunction with these transactions, Eidos recognized a preferred stock warrant liability, tranche liability and an embedded derivative, which were recorded at fair value at inception and remeasured to fair value at each subsequent reporting date until the instruments were settled. For the year ended December 31, 2018, we recorded $1.3 million in other income (expense), net in the consolidated statements of operations related to these 2018 Eidos financing transactions. All of these Eidos financial instruments were settled during 2018. </p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In June 2018, Eidos completed its initial public offering, or the Eidos IPO. All redeemable convertible preferred stock of Eidos was converted into common stock at the closing of the Eidos IPO. As part of the Eidos IPO, we purchased common stock in the amount of $17.0&#160;million. The Eidos Warrant was also net exercised upon the completion of the Eidos IPO. We previously determined that Eidos was a controlled VIE as of December&#160;31, 2017 and through its initial public offering in June 2018, at which time we determined that Eidos is no longer a VIE. In May 2019, we purchased 1,103,848 shares of Eidos common stock from an existing Eidos stockholder for $28.6 million in a private purchase transaction. In July 2019, we purchased 882,353 shares of Eidos common stock from an existing Eidos investor for $26.4 million in a private purchase transaction. Subsequent to the Eidos IPO and through December 31, 2019, we held a majority voting interest in Eidos and consolidate Eidos under the VOE model. </p> <p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">PellePharm, Inc. Transactions: </p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">PellePharm entered into a series of agreements, or the LEO Agreement, with LEO Pharma A/S, or LEO, in November 2018. As part of the LEO Agreement, we granted LEO an exclusive, irrevocable option, or the LEO Call Option, to acquire all of PellePharm&#8217;s shares held by us. The LEO Call Option is exercisable by LEO on or before the occurrence of certain events relating to PellePharm&#8217;s clinical development programs and no later than July&#160;30, 2021. We account for the LEO Call Option as a current liability in our consolidated financial statements because we are obligated to sell our shares in PellePharm to LEO at a pre-determined price, if the option is exercised. The fair value of the LEO Call Option on issuance in November 2018 was $1.9&#160;million and increased to $3.0 million as of December 31, 2018 and increased to $4.1 million as of December 31, 2019. The change in fair value of the LEO Call Option is recorded as part of other expense in our consolidated statements of operations. We remeasure the LEO Call Option to fair value at each subsequent balance sheet date until the LEO Call Option is either exercised or expires. We previously determined that we were the primary beneficiary of PellePharm, as of December&#160;31, 2017 and through the date of execution of the LEO Agreement in November 2018. At the time of execution, we concluded that we are no longer the primary beneficiary of, and thus deconsolidated, PellePharm. Subsequent to the LEO Agreement, we account for our retained investment in common and preferred stock of PellePharm under the equity method and cost method, respectively. Upon adoption ASU 2016-01 in 2019 (see <font style="font-style:italic;">Recently Adopted Accounting Pronouncements</font>), we concluded that our investment in preferred stock of PellePharm did not have a readily available fair value. As a result we started to measure the adjusted cost basis of our retained investment in PellePharm&#8217;s preferred stock&nbsp;&nbsp;at cost less impairment plus or minus observable price changes. Since our investment in common stock was reduced to zero during the first quarter of 2019 as a result of applying the equity method, we subsequently adjusted the cost basis of our preferred stock investment by recording our percentage of net losses consistent with our preferred stock ownership percentage of 61.9% until the adjusted cost basis was also reduced to zero during the remaining period of 2019.</p>
CY2019 us-gaap Use Of Estimates
UseOfEstimates
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Use of Estimates </p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements, and the reported amounts of expenses during the reporting period. Significant estimates and assumptions made in the accompanying consolidated financial statements include, but are not limited to, the fair value of the LEO Call Option liability, the valuation of our stock-based awards, accruals for certain employees&#8217; performance-based milestones, accruals for research and development activities, accruals for contingent milestone payments in our license agreements and income tax uncertainties. We base our estimates on historical experience and on various other assumptions that are believed to be reasonable. Actual results may differ from those estimates or assumptions. </p>
CY2019 dei Entity Incorporation Date Of Incorporation
EntityIncorporationDateOfIncorporation
2019-05-17
CY2019 bbio Minimum Required Percentage Of Voting Interests Of Investee To Exercise Significant Influence
MinimumRequiredPercentageOfVotingInterestsOfInvesteeToExerciseSignificantInfluence
0.20
CY2019 bbio Impairment Charge On Equity And Cost Method Investments
ImpairmentChargeOnEquityAndCostMethodInvestments
0
CY2018 bbio Impairment Charge On Equity And Cost Method Investments
ImpairmentChargeOnEquityAndCostMethodInvestments
0
CY2019 bbio Cash Cash Equivalents And Restricted Cash Maturity Period
CashCashEquivalentsAndRestrictedCashMaturityPeriod
P90D
CY2017Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
91995000
CY2019Q4 us-gaap Restricted Cash
RestrictedCash
424000
CY2018Q4 us-gaap Restricted Cash
RestrictedCash
159000
CY2017Q4 us-gaap Restricted Cash
RestrictedCash
381000
CY2019 us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
0
CY2019 us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
CY2019 bbio Number Of Business Segments
NumberOfBusinessSegments
1
CY2019Q4 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
0
CY2017Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2017Q4 us-gaap Common Stock Value
CommonStockValue
51000
CY2017Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
134495000
CY2017Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-48695000
CY2017Q4 us-gaap Stockholders Equity
StockholdersEquity
85851000
CY2017Q4 us-gaap Minority Interest
MinorityInterest
2498000
CY2016Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2016Q4 us-gaap Common Stock Value
CommonStockValue
21000
CY2016Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
32998000
CY2016Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-18130000
CY2016Q4 us-gaap Stockholders Equity
StockholdersEquity
14889000
CY2016Q4 us-gaap Minority Interest
MinorityInterest
2595000
CY2019Q4 bbio Fair Value Assets Transfers Between Level One Level Two Or Level Three Amount
FairValueAssetsTransfersBetweenLevelOneLevelTwoOrLevelThreeAmount
0
CY2018Q4 bbio Fair Value Assets Transfers Between Level One Level Two Or Level Three Amount
FairValueAssetsTransfersBetweenLevelOneLevelTwoOrLevelThreeAmount
0
CY2019Q4 bbio Fair Value Liabilities Transfers Between Level One Level Two Or Level Three Amount
FairValueLiabilitiesTransfersBetweenLevelOneLevelTwoOrLevelThreeAmount
0
CY2018Q4 bbio Fair Value Liabilities Transfers Between Level One Level Two Or Level Three Amount
FairValueLiabilitiesTransfersBetweenLevelOneLevelTwoOrLevelThreeAmount
0
CY2019Q4 bbio Securities Collateral By Deposits Percentage Maintained By Third Party Custodian
SecuritiesCollateralByDepositsPercentageMaintainedByThirdPartyCustodian
1.02
CY2019Q4 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
307736000
CY2019Q4 us-gaap Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
307736000
CY2019Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
520846000
CY2019Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
254000
CY2019Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
521100000
CY2018Q4 us-gaap Money Market Funds At Carrying Value
MoneyMarketFundsAtCarryingValue
395800
CY2018Q4 us-gaap Marketable Securities
MarketableSecurities
0
CY2018 us-gaap Available For Sale Securities Gross Realized Gain Loss Net
AvailableForSaleSecuritiesGrossRealizedGainLossNet
0
CY2018 bbio Short Term Marketable Securities Contractual Maturities
ShortTermMarketableSecuritiesContractualMaturities
P8M
CY2018 bbio Long Term Marketable Securities Contractual Maturities
LongTermMarketableSecuritiesContractualMaturities
P16M
CY2019 bbio Adjustments Of Carrying Value Of Noncontrolling Interest Additional Paid In Capital
AdjustmentsOfCarryingValueOfNoncontrollingInterestAdditionalPaidInCapital
-28600000
CY2018 bbio Adjustments Of Carrying Value Of Noncontrolling Interest Additional Paid In Capital
AdjustmentsOfCarryingValueOfNoncontrollingInterestAdditionalPaidInCapital
21600000
CY2017 bbio Adjustments Of Carrying Value Of Noncontrolling Interest Additional Paid In Capital
AdjustmentsOfCarryingValueOfNoncontrollingInterestAdditionalPaidInCapital
-8200000
CY2017 bbio Transfers To From Non Controlling Interest
TransfersToFromNonControllingInterest
8969000
CY2017 us-gaap Net Income Loss Attributable To Nonredeemable Noncontrolling Interest
NetIncomeLossAttributableToNonredeemableNoncontrollingInterest
-10510000
CY2018 us-gaap Noncontrolling Interest Increase From Subsidiary Equity Issuance
NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance
99479000
CY2018 us-gaap Net Income Loss Attributable To Nonredeemable Noncontrolling Interest
NetIncomeLossAttributableToNonredeemableNoncontrollingInterest
-26172000
CY2018 us-gaap Minority Interest Decrease From Redemptions
MinorityInterestDecreaseFromRedemptions
44234000
CY2018 bbio Transfers To From Non Controlling Interest
TransfersToFromNonControllingInterest
17850000
CY2018 bbio Conversion Of Redeemable Convertible Noncontrolling Interest To Noncontrolling Interest
ConversionOfRedeemableConvertibleNoncontrollingInterestToNoncontrollingInterest
12252000
CY2019 bbio Transfers To From Non Controlling Interest
TransfersToFromNonControllingInterest
26832000
CY2017 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.340
CY2019 us-gaap Net Income Loss Attributable To Nonredeemable Noncontrolling Interest
NetIncomeLossAttributableToNonredeemableNoncontrollingInterest
-25120000
CY2019 bbio Lease Expiration Month And Year
LeaseExpirationMonthAndYear
2026-10
CY2017Q1 bbio Operating Lease Term Of Contract
OperatingLeaseTermOfContract
P3Y
CY2017Q1 bbio Area Rentable By Lessor Under Operating Lease
AreaRentableByLessorUnderOperatingLease
3900
CY2017Q1 us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
2200000
CY2019Q2 us-gaap Lessee Operating Lease Renewal Term
LesseeOperatingLeaseRenewalTerm
P3Y
CY2019Q2 bbio Lease Extension Month And Year
LeaseExtensionMonthAndYear
2023-04
CY2019Q4 us-gaap Operating Leases Future Minimum Payments Due Current
OperatingLeasesFutureMinimumPaymentsDueCurrent
2811000
CY2019Q4 us-gaap Operating Leases Future Minimum Payments Due In Two Years
OperatingLeasesFutureMinimumPaymentsDueInTwoYears
2515000
CY2019Q4 us-gaap Operating Leases Future Minimum Payments Due In Three Years
OperatingLeasesFutureMinimumPaymentsDueInThreeYears
1812000
CY2019Q4 us-gaap Operating Leases Future Minimum Payments Due In Four Years
OperatingLeasesFutureMinimumPaymentsDueInFourYears
1485000
CY2019Q4 us-gaap Operating Leases Future Minimum Payments Due In Five Years
OperatingLeasesFutureMinimumPaymentsDueInFiveYears
1272000
CY2019Q4 us-gaap Operating Leases Future Minimum Payments Due Thereafter
OperatingLeasesFutureMinimumPaymentsDueThereafter
1816000
CY2019Q4 us-gaap Operating Leases Future Minimum Payments Due
OperatingLeasesFutureMinimumPaymentsDue
11711000
CY2019 us-gaap Lease And Rental Expense
LeaseAndRentalExpense
2800000
CY2018 us-gaap Lease And Rental Expense
LeaseAndRentalExpense
1500000
CY2017 us-gaap Lease And Rental Expense
LeaseAndRentalExpense
400000
CY2019 bbio Potential Milestone Compensation
PotentialMilestoneCompensation
34000000
CY2019 us-gaap Employee Benefits And Share Based Compensation
EmployeeBenefitsAndShareBasedCompensation
0
CY2019Q4 bbio Accrued Termination Charges
AccruedTerminationCharges
0
CY2018Q4 bbio Accrued Termination Charges
AccruedTerminationCharges
0
CY2019Q4 us-gaap Long Term Debt Maturities Repayments Of Principal In Next Twelve Months
LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths
6748000
CY2019Q4 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Two
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo
28825000
CY2019Q4 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Three
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree
50939000
CY2019Q4 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Four
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour
8861000
CY2019Q4 us-gaap Long Term Debt
LongTermDebt
95373000
CY2019Q4 bbio Long Term Debt Maturities Repayments Of Interest
LongTermDebtMaturitiesRepaymentsOfInterest
15850000
CY2019Q4 bbio Long Term Debt Maturities Final End Of Term Payment
LongTermDebtMaturitiesFinalEndOfTermPayment
4523000
CY2019Q4 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
75000000
CY2019 bbio Upfront Payment Received
UpfrontPaymentReceived
10000000
CY2019 bbio Fair Value Of Ordinary Shares Received
FairValueOfOrdinarySharesReceived
3800000
CY2019Q4 bbio One Time Fees Payable
OneTimeFeesPayable
10000000
CY2019Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
10000000
CY2019Q4 us-gaap Operating Lease Right Of Use Asset Statement Of Financial Position Extensible List
OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList
us-gaap:AssetsNoncurrent
CY2019 us-gaap Operating Lease Payments
OperatingLeasePayments
2000000
CY2019Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
8000000
CY2019 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
21374000
CY2018 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
6067000
CY2017 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1841000
CY2019 us-gaap Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
288585000
CY2018 us-gaap Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
169451000
CY2017 us-gaap Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
43832000
CY2019 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
288585000
CY2018 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
169451000
CY2017 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
43832000
CY2019 us-gaap Current Federal Tax Expense Benefit
CurrentFederalTaxExpenseBenefit
0
CY2018 us-gaap Current Federal Tax Expense Benefit
CurrentFederalTaxExpenseBenefit
0
CY2017 us-gaap Current Federal Tax Expense Benefit
CurrentFederalTaxExpenseBenefit
0
CY2019 us-gaap Current Foreign Tax Expense Benefit
CurrentForeignTaxExpenseBenefit
0
CY2018 us-gaap Current Foreign Tax Expense Benefit
CurrentForeignTaxExpenseBenefit
0
CY2017 us-gaap Current Foreign Tax Expense Benefit
CurrentForeignTaxExpenseBenefit
0
CY2019 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.210
CY2018 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.210
CY2019 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.253
CY2018 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.202
CY2017 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.164
CY2019 us-gaap Effective Income Tax Rate Reconciliation Tax Credits Research
EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
0.041
CY2018 us-gaap Effective Income Tax Rate Reconciliation Tax Credits Research
EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
0.016
CY2017 us-gaap Effective Income Tax Rate Reconciliation Tax Credits Research
EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
0.008
CY2019 bbio Effective Income Tax Rate Reconciliation Change In Entity Status
EffectiveIncomeTaxRateReconciliationChangeInEntityStatus
0.017
CY2019 us-gaap Effective Income Tax Rate Reconciliation Tax Exempt Income
EffectiveIncomeTaxRateReconciliationTaxExemptIncome
0.014
CY2018 us-gaap Effective Income Tax Rate Reconciliation Tax Exempt Income
EffectiveIncomeTaxRateReconciliationTaxExemptIncome
0.012
CY2017 us-gaap Effective Income Tax Rate Reconciliation Tax Exempt Income
EffectiveIncomeTaxRateReconciliationTaxExemptIncome
0.011
CY2019 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
-0.001
CY2018 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
-0.012
CY2017 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
-0.014
CY2017 us-gaap Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate
EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate
-0.159
CY2019Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
94335000
CY2018Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
40896000
CY2019Q4 bbio Deferred Tax Assets Amortization Of Assets
DeferredTaxAssetsAmortizationOfAssets
5196000
CY2018Q4 bbio Deferred Tax Assets Amortization Of Assets
DeferredTaxAssetsAmortizationOfAssets
4424000
CY2019Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals
1917000
CY2018Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals
434000
CY2019Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
1820000
CY2018Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
268000
CY2019Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards
DeferredTaxAssetsTaxCreditCarryforwards
18443000
CY2018Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards
DeferredTaxAssetsTaxCreditCarryforwards
3728000
CY2019Q4 us-gaap Deferred Tax Assets Equity Method Investments
DeferredTaxAssetsEquityMethodInvestments
7297000
CY2019Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
210000
CY2018Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
23000
CY2019Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
129218000
CY2018Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
49773000
CY2019Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
128928000
CY2018Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
49755000
CY2019Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
290000
CY2018Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
18000
CY2019Q4 us-gaap Deferred Tax Liabilities Property Plant And Equipment
DeferredTaxLiabilitiesPropertyPlantAndEquipment
290000
CY2018Q4 us-gaap Deferred Tax Liabilities Property Plant And Equipment
DeferredTaxLiabilitiesPropertyPlantAndEquipment
18000
CY2019Q4 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
290000
CY2018Q4 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
18000
CY2019 bbio Operating Loss Carryforwards Expiration Year
OperatingLossCarryforwardsExpirationYear
2037
CY2019 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
79200000
CY2018Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
1182000
CY2017Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
296000
CY2019 bbio Unrecognized Tax Benefits Increases Decreases Resulting From Prior Period Tax Positions
UnrecognizedTaxBenefitsIncreasesDecreasesResultingFromPriorPeriodTaxPositions
2913000
CY2018 bbio Unrecognized Tax Benefits Increases Decreases Resulting From Prior Period Tax Positions
UnrecognizedTaxBenefitsIncreasesDecreasesResultingFromPriorPeriodTaxPositions
-42000
CY2019 us-gaap Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
3509000
CY2018 us-gaap Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
928000
CY2019Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
7604000
CY2019 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Expense
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense
0
CY2017Q4 us-gaap Tax Cuts And Jobs Act Of2017 Change In Tax Rate Deferred Tax Asset Income Tax Expense
TaxCutsAndJobsActOf2017ChangeInTaxRateDeferredTaxAssetIncomeTaxExpense
6800000
CY2019 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
10722263
CY2018 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
5355166
CY2017 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
6633375

Files In Submission

Name View Source Status
0001564590-20-008260-index-headers.html Edgar Link pending
0001564590-20-008260-index.html Edgar Link pending
0001564590-20-008260.txt Edgar Link pending
0001564590-20-008260-xbrl.zip Edgar Link pending
bbio-10k_20191231.htm Edgar Link pending
bbio-20191231.xml Edgar Link completed
bbio-20191231.xsd Edgar Link pending
bbio-20191231_cal.xml Edgar Link unprocessable
bbio-20191231_def.xml Edgar Link unprocessable
bbio-20191231_lab.xml Edgar Link unprocessable
bbio-20191231_pre.xml Edgar Link unprocessable
bbio-ex1014a_1051.htm Edgar Link pending
bbio-ex1028_1188.htm Edgar Link pending
bbio-ex1033_1343.htm Edgar Link pending
bbio-ex1038_759.htm Edgar Link pending
bbio-ex1039_1187.htm Edgar Link pending
bbio-ex21_758.htm Edgar Link pending
bbio-ex231_9.htm Edgar Link pending
bbio-ex311_757.htm Edgar Link pending
bbio-ex312_756.htm Edgar Link pending
bbio-ex321_755.htm Edgar Link pending
bbio-ex322_754.htm Edgar Link pending
bbio-ex44_1189.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
gbftfbo1m3gl000001.jpg Edgar Link pending
gnc1abfnre5o000001.jpg Edgar Link pending
gnc1abfnre5o000002.jpg Edgar Link pending
gnc1abfnre5o000003.jpg Edgar Link pending
gnc1abfnre5o000004.jpg Edgar Link pending
gnc1abfnre5o000005.jpg Edgar Link pending
gnc1abfnre5o000006.jpg Edgar Link pending
gnc1abfnre5o000007.jpg Edgar Link pending
gnc1abfnre5o000008.jpg Edgar Link pending
gnc1abfnre5o000009.jpg Edgar Link pending
gnc1abfnre5o000010.jpg Edgar Link pending
gnc1abfnre5o000011.jpg Edgar Link pending
gnc1abfnre5o000012.jpg Edgar Link pending
gnc1abfnre5o000013.jpg Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R66.htm Edgar Link pending
R67.htm Edgar Link pending
R68.htm Edgar Link pending
R69.htm Edgar Link pending
R7.htm Edgar Link pending
R70.htm Edgar Link pending
R71.htm Edgar Link pending
R72.htm Edgar Link pending
R73.htm Edgar Link pending
R74.htm Edgar Link pending
R75.htm Edgar Link pending
R76.htm Edgar Link pending
R77.htm Edgar Link pending
R78.htm Edgar Link pending
R79.htm Edgar Link pending
R8.htm Edgar Link pending
R80.htm Edgar Link pending
R81.htm Edgar Link pending
R82.htm Edgar Link pending
R83.htm Edgar Link pending
R84.htm Edgar Link pending
R85.htm Edgar Link pending
R86.htm Edgar Link pending
R87.htm Edgar Link pending
R88.htm Edgar Link pending
R89.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending